Program
All times below are in US Eastern Time – to review times in your own time zone, please use the green buttons below.
A PDF version of the program will be made available soon.
PROGRAM AT-A-GLANCE
Monday, October 11, 2021 – all times in US Eastern Time
Session/Lecture
10:00 ET
10:05
Part 1: ATN Biomarkers
Part 2: Ocular Approaches and Emerging Protein Biomarkers of ADRD
5 min for questions at the end of each talk
10:05
10:10
10:30
10:50
11:10
11:20
11:40
12:00
12:05
12:25
12:45
12:50
13:10
13:20
13:40
14:00
14:20
14:30
15:00
15:05
Chair/Speaker
10:00 ET
10:05
Part 1 Chair: Robert Dean, MD, PhD, Robert A. Dean Consulting
Part 2 Chair: Anka Ehrhardt, PhD, CHDI
10:05
Anka Ehrhardt, PhD, CHDI
10:10
10:30
Steve Zicha, PhD, Takeda
10:50
11:10
11:20
11:40
12:00
12:05
12:25
Catherine Bornbaum, PhD, MBA, Retispec
12:45
12:50
13:10
13:20
13:40
14:00
Leyla Anderson, MD, PhD, NeuroVision
14:20
Thomas Montine, MD, Stanford University
14:30
Anka Ehrhardt, PhD, CHDI
15:00
Anka Ehrhardt, PhD, CHDI
15:05
Tuesday, October 12, 2021 – all times in US Eastern Time
Session/Lecture
10:00
Part 1: Peripheral Molecular Biomarkers of ADRD
Part 2: Misfolded Proteins and Biomarkers of FTD
5 min for questions at the end of each talk
10:00
10:05
10:25
10:45
11:05
11:25
11:45
12:05
12:25
12:55
13:15
13:20
13:40
14:00
14:20
14:30
15:00
15:05
Chair/Speaker
10:00
Part 1 Chair: James Gallarda, PhD, Dx Consultancy
Part 2 Chair: Penny Dacks, PhD, AFTD
10:00
10:05
10:25
10:45
11:05
Marta Blanch, PhD, ADmit Therapeutics S.L.
11:25
11:45
12:05
12:25
12:55
13:15
13:20
13:40
14:00
14:20
Danielle Graham, PhD, Biogen
14:30
15:00
Penny Dacks, PhD, AFTD
15:05
Tuesday, October 12, 2021 – all times in US Eastern Time
Session/Lecture
18:00
Part 3: Updates from the Pacific Rim
5 min for questions at the end of each talk
18:00
18:05
18:25
18:30
18:50
19:10
19:15
Chair/Speaker
18:00
Part 3 Chair: Tetsuyuki Maruyama, PhD, Alzheimer’s Disease Data Initiative
18:00
18:05
18:25
18:30
18:50
19:10
19:15
Wednesday, October 13, 2021 – all times in US Eastern Time
Session/Lecture
9:00
10:00
Digital Biomarkers
5 min for questions at the end of each talk
10:00
10:05
10:25
10:45
11:05
11:25
11:45
12:15
12:30
Chair/Speaker
9:00
10:00
Chair: Lampros Kourtis, PhD, Circadic
10:00
10:05
10:25
10:45
11:05
11:25
Rhoda Au, PhD, Boston University
Ihab Hajjar, MD, Emory University
11:45
12:15
Howard Fillit, MD, Alzheimer's Drug Discovery Foundation
12:30
PROGRAM DETAILS
WELCOME NOTES
Monday, October 11, 2021
10:00 US Eastern Time
CONCLUDING REMARKS
Wednesday, October 13, 2021
12:15 US Eastern Time
Organizers/Hosts
Howard Fillit
Alzheimer’s Drug Discovery Foundation
Niranjan Bose
Gates Ventures
SESSION I
Part 1: ATN Biomarkers
PART I: This session with focus on the established biomarkers of AD pathology (amyloid, Tau and neurofilament) showcasing projects these proteins either in a stand alone test or in a combined panel.
Part 2: Ocular Approaches and Emerging Protein Biomarkers of ADRD
This session will focus on the approaches to measure proteins of interest in the eye as well understanding vasculature of different eye vessels and how they contribute to our understanding of detecting ADRD. The emerging biomarker section focusses on neuroinflammatory biomarkers and biomarkers of the contact system – all of which will aid with different diagnosis.

Robert Dean
Robert A. Dean Consulting
CO-CHAIR (Part I)

Anka G. Ehrhardt, PhD
CHDI Mgmt/CHDI Fnd.
CO-CHAIR (Part II)
Monday, October 11, 2021
10:05 – 15:30 US Eastern Time




Henrik Zetterberg
Univ of Gothenburg
Plasma Amyloid Beta Ratio as a Diagnostic Test for Alzheimer-related Amyloid Pathology
Wesley Horton
Found. for NIH
Plasma Aβ and pTau Biomarkers As Drug Development Tools to Define Clinical and Pathological Trajectories in AD
Stephen Zicha
Takeda
Kaj Blennow
Univ of Gothenburg
Tau and p-tau as Alzheimer Biomarkers – Assays, Methodological Aspects and Clinical Performance


Leyla Anderson
NeuroVision Imaging
Validation and Commercialization of a Novel Blood-based, Ultra-multiplex Laboratory Developed Test (LDT) for the Prediction of Cerebral Amyloid Status before Clinical Onset of Dementia
Manu Vandijck
FujireBio



Thomas MacGillvray
University of Edinburgh
Investigating Novel Neuro-retinal Biomarkers for Alzheimer’s Disease
Eliav Shaked
RetiSpec
Catherine Bornbaum
RetiSpec

Cecilia Lee
Univ. of Washington




Erin Norris
The Rockefeller Univ.
Amber Murray
Biological Dynamics
Blaine Roberts
Emory University
Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation
Leyla Anderson
NeuroVision Imaging
Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation


Joe Phongpreecha
Stanford Univ.
Diana Kerwin
GAP Innovations, PBC
SESSION II
Part 1: Peripheral Molecular Biomarkers
This section will focus on emerging molecular biomarkers such as miRNA, mitochondrial DNA and epigenetic changes that will enhance our understanding of disease


Part 2: Misfolded Proteins and Biomarkers of FTD
This section focusses on misfolded proteins as well biomarkers of interest in the FTD space. These will enable selection of right patients into clinical trials, a need in the area of diseases such as FTD.
James Gallarda
Dx Consultancy
CO-CHAIR (Part 1)
Penny Dacks
AFTD
CO-CHAIR (Part 2)
Tuesday, October 12, 2021
10:00 – 15:30 US Eastern Time





Asael Lubotzky
Hebrew University
Non-invasive Detection of Brain Cell Death Using Methylation Patterns of Circulating DNA: a Novel Blood Test for Early Detection of Alzheimer’s Disease
Hüseyin Firat
Amoneta Dx
Bruno Steinkraus
Hummingbird Diagnostics
Marta Barrachina
ADmit Therapeutics
Marta Blanch
ADmit Therapeutics





Laura Ibanez
Washington Univ
Kira Sheinerman
Diamir Biosciences
Gregory Penner
NeoNeuro
Use of Aptamarkers to Predict Brain Amyloid Deposition
Russell Lebovitz
Amprion
Judith Steen
Boston Children’s Hospital

Rachel Acuna-Narvaez
Bluefield Project to Cure FTD
The Neurofilament Surveillance Project (NSP): Lessons Learned during Year 1 of our Blood Biomarker Study in Familial Frontotemporal Lobar Degeneration



Qinwen Mao
Univ. of Utah
Wesley Horton
Found. for NIH
Danielle Graham
Biogen
SESSION II
Part 3: Updates from the Pacific Rim
A collection of research in ocular, digital and neuroinflammation biomarkers from investigators located in the Asia Pacific Rim.

Tetsuyuki Maruyama
Alzheimer’s Disease Data Initiative
CHAIR (Part 3)
Tuesday, October 12, 2021
18:00 – 19:15 US Eastern Time



Peter Van Wijngaarden
Ctr for Eye Res AU
Retinal Imaging Biomarkers of Alzheimer’s Disease
Matthew Pase
Monash University
Plasma Neuroinflammatory Biomarkers for the Diagnosis of Dementia Subtypes
Guoliang Xing
Chinese Univ HK
SESSION III
Digital Biomarkers
This session will showcase projects that enable the objective and quantifiable measure of psychological and behavioral changes that relate to biological changes associated with disease.

Lampros Kourtis
Circadic
CHAIR
Wednesday, October 13, 2021
9:00 – 12:30 US Eastern Time




Ramit Ravona-Springer
Sheba Medical Center
Chris Edgar
Cogstate
Rhoda Au
Boston University
Larsson Omberg
Sage Bionetworks
Collaborative Benchmarking and Validation of Digital Biomarkers





Caroline Lustenberger
ETH Zuerich
Nicklas Linz
ki elements
Zoe Kourtzi
Alzheimer’s Research UK
Ihab Hajjar
Emory University
Speech & Language Consortium
Ioannis Tarnanas
Altoida
Digital Neuro Signatures to Detect Subtle Alterations in the Early Stages of Alzheimer’s Disease: Altoida’s Micro-movements for Preclinical AD


Jennifer Rae Myers
Neurotrack
Christy Sheehy
C. Light Technologies